Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 349 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Attention Control Clear all
Completed Not applicable Interventional Results available

Brief Behavioral Treatment for Insomnia in Cancer Survivors

NCT03810365
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Brief behavioral treatment for insomnia, Healthy Eating Control
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 22, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.

NCT00566449
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Placebo, JNJ-31001074
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
21
States / cities
Irvine, California • Lafayette, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Oct 22, 2026, 7:14 PM EDT
Completed No phase listed Observational

Attention-Deficit/Hyperactivity Disorder (ADHD) Brain Activity Changes to Psychostimulants

NCT01310439
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Not listed
Lead sponsor
Hartford Hospital
Other
Eligibility
13 Years to 50 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Oct 22, 2026, 7:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Genetics on Metformin Pharmacokinetics

NCT00187798
View directory record Official record
Conditions
Other Conditions That May Be A Focus of Clinical Attention
Interventions
Metformin HCl
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Oct 22, 2026, 7:14 PM EDT
Recruiting Phase 4 Interventional

Effect of Local Anesthetic Concentration on Rebound Pain

NCT07146685
View directory record Official record
Conditions
Rebound Pain, Shoulder Arthroplasty, Interscalene Block
Interventions
Bupivacaine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 7:14 PM EDT
Completed Phase 4 Interventional Results available

Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder

NCT02048241
View directory record Official record
Conditions
Intermittent Explosive Disorder, Childhood Aggression, Oppositional Defiant Disorder, Attention Deficit Disorder
Interventions
Parent Management Training, Placebo, Intuniv
Behavioral · Other · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
6 Years to 12 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 22, 2026, 7:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multi-limb Dual-task Control in Parkinson's Disease

NCT03662009
View directory record Official record
Conditions
Parkinson Disease
Interventions
multilimb dual task
Other
Lead sponsor
A.T. Still University of Health Sciences
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 22, 2026, 7:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study for Naltrexone on the Abuse Potential of Methylphenidate

NCT03769064
View directory record Official record
Conditions
Naltrexone, Methylphenidate Abuse
Interventions
Placebo, Methylphenidate 60 mg, Treatment Phase Sequence 4213, Treatment Phase Sequence 2134, Treatment Phase Sequence 1342, Treatment Phase Sequence 3421
Drug
Lead sponsor
Avekshan LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 22, 2026, 7:14 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults

NCT01345864
View directory record Official record
Conditions
Healthy
Interventions
Scopolamine + Donepezil Placebo + PF-04995274 Placebo, Scopolamine + Donepezil 5 mg + PF-04995274 Placebo, Scopolamine + Donepezil 10mg + PF-04995274 Placebo, Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg, Scopolamine + Donepezil Placebo + PF-04995274 15 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 22, 2026, 7:14 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)

NCT01421498
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye Disease
Interventions
Lifitegrast, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Waterbury, Connecticut • Louisville, Kentucky • Augusta, Maine + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 22, 2026, 7:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adolescent Changes in Brain and Behavior in Boys and Girls With ADHD

NCT05927506
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Other
Behavioral
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
12 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 22, 2026, 7:14 PM EDT
Active, not recruiting Not applicable Interventional

Efficacy of the Apollo System for Children With ADHD

NCT05308706
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
8 weeks of home based use.
Device
Lead sponsor
Michigan State University
Other
Eligibility
8 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 22, 2026, 7:14 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Network Control TMS fMRI

NCT05736458
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Working Memory
Interventions
Transcranial Magnetic Stimulation (TMS), High controllability TMS target
Device · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 28 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 22, 2026, 7:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

NCT00300274
View directory record Official record
Conditions
Graft Rejection
Interventions
everolimus, mycophenolate mofetil, cyclosporine, corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Oct 22, 2026, 7:14 PM EDT
Completed Phase 3 Interventional Results available

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

NCT01176240
View directory record Official record
Conditions
Orthostatic Hypotension, Parkinson's Disease
Interventions
Droxidopa, Placebo
Drug · Other
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
60
States / cities
Alabaster, Alabama • Gilbert, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 22, 2026, 7:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Cognition and Control in Youths

NCT03393390
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder
Interventions
Clinical Assessment Visit, fMRI scan
Diagnostic Test · Other
Lead sponsor
University of Michigan
Other
Eligibility
6 Years to 18 Years
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 22, 2026, 7:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment

NCT00688376
View directory record Official record
Conditions
Attention Impairment
Interventions
Donepezil hydrochloride, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Stanford, California • Miami, Florida • Minneapolis, Minnesota + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 22, 2026, 7:14 PM EDT
Enrolling by invitation Phase 2 Interventional

Extending the Reach of Evidence-based Practices to Support Student's Attention and Behavior Through Technology

NCT06886217
View directory record Official record
Conditions
Control Condition, Intervention Condition
Interventions
Collaborative Life Skills dHealth tool (CLS-D)
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
7 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 22, 2026, 7:14 PM EDT
Recruiting Phase 4 Interventional

Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints

NCT05776056
View directory record Official record
Conditions
Posttraumatic Stress Disorder (PTSD)
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 22, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01364662
View directory record Official record
Conditions
Impulsive Aggression Comorbid With ADHD
Interventions
SPN-810, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
27
States / cities
Dothan, Alabama • Los Angeles, California • Santa Ana, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 22, 2026, 7:14 PM EDT
Completed Phase 4 Interventional

Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

NCT00228046
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Oppositional Defiant Disorder
Interventions
Divalproex Sodium, Methylphenidate, Dextroamphetamine, Mixed Amphetamine Salts, Family Counseling, Behavior Management Training with Parents
Drug · Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
6 Years to 14 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New Hyde Park, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 22, 2026, 7:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)

NCT04647903
View directory record Official record
Conditions
ADHD, Narcolepsy
Interventions
ADAIR 10 mg IR tablets, d-amphetamine sulfate, Placebo
Drug
Lead sponsor
Vallon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 22, 2026, 7:14 PM EDT
Completed Phase 3 Interventional

Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults

NCT00048360
View directory record Official record
Conditions
Attention Deficit Disorder
Interventions
Extended-release bupropion hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
21
States / cities
Phoenix, Arizona • Chula Vista, California • Lafayette, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 22, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence

NCT00421603
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Adderall-XR and Topiramate, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 22, 2026, 7:14 PM EDT